Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Filippo de Marinis et al.|Journal of Clinical Oncology|2024Cited by 137
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 TrialAlexander Drilon, Byoung Chul Cho, D. Ross Camidge et al.|Journal of Thoracic Oncology|2024Cited by 0